abstract |
The present invention provides methods for reducing or preventing a patient's humoral immune response from developing antibodies that neutralize or limit the efficacy of therapeutic molecules. The methods are based on the use of anti-CD20 antibodies to deplete antibody-producing B-cells in a patient. Suitable dosage and therapeutic regiments are also provided. The present invention further provides kits with reagents for practicing the disclosed methods. |